Bryan Bienvenu is an Oncology physician affiliated with Mary Bird Perkins Cancer Center. OpenAlex indexes 7 publications with 223 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4950 Essen Lane
Baton Rouge, LA 708093482
Telephone
225-767-1311Provider last certified this registry record 13 Jan 2021.
Industry payments
30 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20259 payments
- PFIZER INC.Program year20257 payments
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.1%PD-1 inhibitor30.2%Pembrolizumab100%Part B, office-administered≥12 patientsLeukocyte Growth Factor10.5%Eflapegrastim-xnst100%Part B, office-administered≥11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
35.1%Other antiemetics28%Fosaprepitant100%Part B, office-administered≥23 patientsSerotonin-3 Receptor Antagonist4.4%Palonosetron hcl55%Ondansetron hydrochloride39%Ondansetron Hcl5%Ondansetron Odt1%Part D + Part B<11 patients+ 10 more classes in this area
Musculoskeletal
7%RANK Ligand Inhibitor6.8%Denosumab100%Part B, office-administered≥18 patientsMuscle Relaxant0.1%Methocarbamol46%Cyclobenzaprine Hcl32%Carisoprodol21%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A phase IIb trial of coix seed injection for advanced pancreatic cancer.
Journal of Clinical Oncology
2013 - Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer
Clinical Colorectal Cancer
2011 - Phase I and Pharmacokinetic Study of the Novel Oral Cell-Cycle Inhibitor Ro 31-7453 in Patients With Advanced Solid Tumors
Journal of Clinical Oncology
2004
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”